The authors also confirmed that after further HA modification, the obtained nanocomposites could target CD44-overexpressing cancer cells and achieve drug release mediated by HAase, further leading to enhanced tumor elimination (Figure 6(a)). The gene discussed is CD44; the disease is neoplasm.